← All trials
NCT04036019
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 13, 2019
- Primary completion
- May 1, 2021
- Completion date
- Jul 30, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- Huazhong University of Science and TechnologyOverall official - principal investigator
- Huazhong University of Science and TechnologyReponsible party - principal investigator
- Cellular Biomedicine Group Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.